{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:17:02Z","timestamp":1792815422361,"version":"4.5.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40265-026-02333-x","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T02:23:48Z","timestamp":1779675828000},"page":"1379-1384","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Culmerciclib: First Approval"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1028-8594","authenticated-orcid":false,"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"issue":"10226","key":"2333_CR1","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","volume":"395","author":"LM Spring","year":"2020","unstructured":"Spring LM, Wander SA, Andre F, et al. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020;395(10226):817\u201327.","journal-title":"Lancet"},{"issue":"2","key":"2333_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","volume":"21","author":"L Morrison","year":"2024","unstructured":"Morrison L, Loibl S, Turner NC. The CDK4\/6 inhibitor revolution - a game-changing era for breast cancer treatment. Nat Rev Clin Oncol. 2024;21(2):89\u2013105.","journal-title":"Nat Rev Clin Oncol"},{"key":"2333_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104324","author":"R Gerosa","year":"2024","unstructured":"Gerosa R, De Sanctis R, Jacobs F, et al. Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions. Crit Rev Oncol Hematol. 2024. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104324.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"2333_CR4","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.ccell.2021.08.009","volume":"39","author":"K Freeman-Cook","year":"2021","unstructured":"Freeman-Cook K, Hoffman RL, Miller N, et al. Expanding control of the tumor cell cycle with a CDK2\/4\/6 inhibitor. Cancer Cell. 2021;39(10):1404-21 e11.","journal-title":"Cancer Cell"},{"key":"2333_CR5","unstructured":"Chia Tai Tianqing Pharmaceutical Group. Culmerciclib capsules (\u8d5b\u5766\u6b23\u00ae): Chinese prescribing information. 2025. https:\/\/www.cttq.com\/product\/zhongliu-detail-25449.htm. Accessed 27 Mar 2026."},{"key":"2333_CR6","unstructured":"Sino Biopharmaceutical. Culmerciclib capsule approved for marketing [media release]. 12 Dec 2025. https:\/\/www.en.sinobiopharm.com\/userfiles\/files\/E25123723-Sino%20Bio-PA.pdf."},{"key":"2333_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2024.129769","volume":"107","author":"Z Xu","year":"2024","unstructured":"Xu Z, Liu Y, Song B, et al. Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor. Bioorg Med Chem Lett. 2024;107:129769.","journal-title":"Bioorg Med Chem Lett"},{"key":"2333_CR8","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S434973","author":"W Hu","year":"2023","unstructured":"Hu W, Wang L, Luo J, et al. The potent novel CDK4\/6 inhibitor TQB3616 in hormone receptor positive breast cancer: preclinical characterization with in vitro and human tumor xenograft models. Breast Cancer (Dove Med Press). 2023. https:\/\/doi.org\/10.2147\/BCTT.S434973.","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"2333_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2025.1586368","volume":"16","author":"J Dai","year":"2025","unstructured":"Dai J, Zhou Y, Zhang L, et al. The food effect on the pharmacokinetics of TQB3616 capsule in Chinse healthy subjects: a randomized, open-label, single-center, two-period, two-sequence crossover phase I clinical trial. Front Pharmacol. 2025;16:1\u20139.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2333_CR10","first-page":"1","volume":"10","author":"Y Yin","year":"2025","unstructured":"Yin Y, Zhang Q, Sun T, et al. Novel CDK2\/4\/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial. Signal Transduct Target Ther. 2025;10(1):1\u201311.","journal-title":"Signal Transduct Target Ther"},{"key":"2333_CR11","doi-asserted-by":"crossref","unstructured":"Song E, Yin Y, Zhao J, et al. Culmerciclib plus fulvestrant as first-line treatment for HR+\/HER2- advanced breast cancer: a phase III trial (CULMINATE-2) [abstract no. LBA25]. Ann Oncol. 2025;36(Suppl 2):S1569\u201370.","DOI":"10.1016\/j.annonc.2025.09.035"},{"key":"2333_CR12","doi-asserted-by":"crossref","unstructured":"Chen J, Zhou Y, Zhang X, et al. Phase II study of the CDK2\/4\/6 inhibitor TQB3616 capsules in patients with dedifferentiated liposarcomas (DDLPS) [abstract no. 1731P]. Ann Oncol. 2024;35(Suppl 2):S1037.","DOI":"10.1016\/j.annonc.2024.08.1823"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02333-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02333-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02333-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:49:58Z","timestamp":1784198998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02333-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2333"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02333-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yahiya Y. Syed is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}